A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Bristol-Myers Squibb
Bristol-Myers Squibb
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
Novartis
Verastem, Inc.
M.D. Anderson Cancer Center
Novartis
Revolution Medicines, Inc.
M.D. Anderson Cancer Center
Genfleet Therapeutics (Shanghai) Inc.
M.D. Anderson Cancer Center
University of Chicago
Mirati Therapeutics Inc.
Eli Lilly and Company
Bristol-Myers Squibb
Nektar Therapeutics
Menarini Group
NuCana plc
HiberCell, Inc.
ImmunityBio, Inc.
Erasca, Inc.
ImmunityBio, Inc.
Roswell Park Cancer Institute
Eli Lilly and Company
NSABP Foundation Inc
NKGen Biotech, Inc.
Amsterdam UMC, location VUmc
Daiichi Sankyo
Gilead Sciences
Western Regional Medical Center
Seagen Inc.
Array BioPharma
Massachusetts General Hospital
Bristol-Myers Squibb
Merck KGaA, Darmstadt, Germany
Bristol-Myers Squibb
Hoosier Cancer Research Network
Merck KGaA, Darmstadt, Germany
Medical University Innsbruck